Artivion (AORT) 10-Q 29 Apr 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 23, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Central Index Key	784199
Entity Registrant Name	CRYOLIFE INC
Trading Symbol	cry
Entity Common Stock, Shares Outstanding		28,332,566

Summary_Consolidated_Statement

Summary Consolidated Statements Of Operations And Comprehensive Income (USD $)	3 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Products	$19,391,000	$19,455,000
Preservation services	14,440,000	16,276,000
Total revenues	33,831,000	35,731,000
Cost of products and preservation services:
Products	5,033,000	3,801,000
Preservation services	9,131,000	9,457,000
Total cost of products and preservation services	14,164,000	13,258,000
Gross margin	19,667,000	22,473,000
Operating expenses:
General, administrative, and marketing	18,969,000	18,275,000
Research and development	2,252,000	2,502,000
Total operating expenses	21,221,000	20,777,000
Operating (loss) income	-1,554,000	1,696,000
Interest expense	30,000	61,000
Interest income	-3,000	-3,000
Other expense (income), net	192,000	-99,000
(Loss) income before income taxes	-1,773,000	1,737,000
Income tax (benefit) expense	-1,499,000	678,000
Net (loss) income	-274,000	1,059,000
(Loss) income per common share:
Basic	($0.01)	$0.04
Diluted	($0.01)	$0.04
Dividends declared per common share	$0.03	$0.03
Weighted-average common shares outstanding:
Basic	27,523	27,376
Diluted	27,523	28,463
Other comprehensive loss	-117,000	-35,000
Comprehensive (loss) income	($391,000)	$1,024,000

Summary_Consolidated_Balance_S

Summary Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$32,413	$33,375
Restricted securities	828	884
Receivables, net	21,646	22,863
Inventories	13,513	12,739
Deferred preservation costs	24,696	25,196
Deferred income taxes	6,210	6,210
Prepaid expenses and other	4,043	4,761
Total current assets	103,349	106,028
Property and equipment, net	12,013	12,002
Restricted cash	5,000	5,000
Goodwill	11,365	11,365
Patents, net	1,724	1,784
Trademarks and other intangibles, net	18,589	19,496
Deferred income taxes	15,894	15,659
Other	5,269	4,823
Total assets	173,203	176,157
Current liabilities:
Accounts payable	3,967	4,543
Accrued compensation	3,586	5,406
Accrued procurement fees	4,634	4,675
Accrued expenses and other	4,609	5,583
Deferred income	406	420
Total current liabilities	17,202	20,627
Other	7,150	6,845
Total liabilities	24,352	27,472
Commitments and contingencies
Shareholders' equity:
Preferred stock
Common stock (issued shares of 29,584 in 2015 and 29,229 in 2014)	296	292
Additional paid-in capital	138,016	135,227
Retained earnings	21,644	22,768
Accumulated other comprehensive loss	-238	-121
Treasury stock at cost (shares of 1,230 in 2015 and 1,101 in 2014)	-10,867	-9,481
Total shareholders' equity	148,851	148,685
Total liabilities and shareholders' equity	$173,203	$176,157

Summary_Consolidated_Balance_S1

Summary Consolidated Balance Sheets (Parenthetical)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary Consolidated Balance Sheets [Abstract]
Common stock, shares issued	29,584	29,229
Treasury stock, shares	1,230	1,101

Summary_Consolidated_Statement1

Summary Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net cash flows from operating activities:
Net (loss) income	($274)	$1,059
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	1,555	1,462
Non-cash compensation	1,137	845
Other non-cash adjustments to income	594	-359
Changes in operating assets and liabilities:
Receivables	1,217	-2,693
Inventories and deferred preservation costs	-897	-821
Prepaid expenses and other assets	272	-430
Accounts payable, accrued expenses, and other liabilities	-2,306	-1,101
Net cash flows provided by (used in) operating activities	1,298	-2,038
Net cash flows from investing activities:
Capital expenditures	-1,055	-1,037
Other	-495	-642
Net cash flows used in investing activities	-1,550	-1,679
Net cash flows from financing activities:
Cash dividends paid	-850	-772
Proceeds from exercise of stock options and issuance of common stock	683	357
Other	-449	-705
Net cash flows used in financing activities	-616	-1,120
Effect of exchange rate changes on cash	-94	-43
Decrease in cash and cash equivalents	-962	-4,880
Cash and cash equivalents, beginning of period	33,375	37,643
Cash and cash equivalents, end of period	$32,413	$32,763

Basis_Of_Presentation

Basis Of Presentation	3 Months Ended
	Mar. 31, 2015
Basis Of Presentation [Abstract]
Basis Of Presentation	1.  Basis of Presentation
	The accompanying summary consolidated financial statements include the accounts of CryoLife, Inc. and its subsidiaries (“CryoLife,” the “Company,” “we,” or “us”).  All significant intercompany accounts and transactions have been eliminated in consolidation.  The accompanying Summary Consolidated Balance Sheet as of December 31, 2014 has been derived from audited financial statements.  The accompanying unaudited summary consolidated financial statements as of and for the three months ended March 31, 2015 and 2014 have been prepared in accordance with (i) accounting principles generally accepted in the U.S. for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”).  Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete presentation of financial statements.  In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.  These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in CryoLife’s Annual Report on Form 10-K for the year ended December 31, 2014.

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2015
Financial Instruments [Abstract]
Financial Instruments	2.  Financial Instruments
	The following is a summary of the Company’s financial instruments measured at fair value (in thousands):
	31-Mar-15	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	20,023	$	--	$	--	$	20,023
	Restricted securities:
	Money market funds		828		--		--		828
	Total assets	$	20,851	$	--	$	--	$	20,851
	31-Dec-14	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	18,213	$	--	$	--	$	18,213
	Restricted securities:
	Money market funds		884		--		--		884
	Total assets	$	19,097	$	--	$	--	$	19,097
	The Company used prices quoted from its investment management companies to determine the Level 1 valuation of its investments in money market funds.

Cash_Equivalents_And_Restricte

Cash Equivalents And Restricted Cash And Securities	3 Months Ended
	Mar. 31, 2015
Cash Equivalents And Restricted Cash And Securities [Abstract]
Cash Equivalents And Restricted Cash And Securities	3.  Cash Equivalents and Restricted Cash and Securities
	The following is a summary of cash equivalents and restricted cash and securities (in thousands):
				Unrealized		Estimated
				Holding		Market
	31-Mar-15	Cost Basis		Gains		Value
	Cash equivalents:
	Money market funds	$	20,023	$	--	$	20,023
	Restricted cash and securities:
	Cash		5,000		--		5,000
	Money market funds		828		--		828
				Unrealized		Estimated
				Holding		Market
	31-Dec-14	Cost Basis		Gains		Value
	Cash equivalents:
	Money market funds	$	18,213	$	--	$	18,213
	Restricted cash and securities:
	Cash		5,000		--		5,000
	Money market funds		884		--		884
	As of March 31, 2015 and December 31, 2014  $828,000 and $884,000, respectively, of the Company’s money market funds were designated as short-term restricted securities due to a contractual commitment to hold the securities as pledged collateral relating primarily to international tax obligations.  As of March 31, 2015 and December 31, 2014  $5.0 million of the Company’s cash was designated as long-term restricted cash due to a financial covenant requirement under the Company’s credit agreement with General Electric Capital Corporation (“GE Capital”), as discussed in Note 11.  This restriction will lapse upon expiration of the credit agreement with GE Capital on September 26, 2019.
	There were no gross realized gains or losses on cash equivalents in the three months ended March 31, 2015 and 2014.  As of March 31, 2015 $234,000 of the Company’s restricted securities had a maturity date within three months, and $594,000 of the Company’s restricted securities had a maturity date of between three months and one year.  As of December 31, 2014 $622,000 of the Company’s restricted securities had a maturity date within three months, and $262,000 of the Company’s restricted securities had a maturity date between three months and one year.  As of March 31, 2015 and December 31, 2014  $5.0 million of the Company’s restricted cash had no maturity date.

Distribution_Agreements

Distribution Agreements	3 Months Ended
	Mar. 31, 2015
Distribution Agreements [Abstract]
Distribution Agreements	4.  Distribution Agreements
	ProCol Distribution Agreement
	In 2014 CryoLife acquired the exclusive worldwide distribution rights for ProCol® Vascular Bioprosthesis (“ProCol”) from Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe”).  The agreement between CryoLife and Hancock Jaffe (the “HJ Agreement”) has an initial three-year term and is renewable for two one-year periods at CryoLife’s option.  Per the terms of the HJ Agreement, CryoLife has the option to acquire the ProCol product line from Hancock Jaffe beginning in March 2016.
	ProCol, which is approved for sale in the U.S., is a biological graft derived from a bovine mesenteric vein that provides vascular access for end-stage renal disease (“ESRD”) hemodialysis patients.  It is intended for the creation of a bridge graft for vascular access subsequent to at least one previously failed prosthetic access graft.  ProCol is complementary to the Company’s Hemodialysis Reliable Outflow Graft (“HeRO® Graft”), which also serves patients with ESRD; however, ProCol provides vascular access for ESRD patients in an earlier-stage of treatment protocol than the HeRO Graft.
	In accordance with the terms of the HJ Agreement, CryoLife made payments to Hancock Jaffe of $1.7 million during 2014 and $576,000 in January 2015.  In exchange for these payments, CryoLife obtained the right to receive a designated amount of ProCol inventory for resale, a portion of which the Company received in 2014 and 2015.  Subsequent to this initial inventory purchase, CryoLife can purchase additional units from Hancock Jaffe at an agreed upon transfer price.  The Company began limited distribution of ProCol in the second quarter of 2014.  On September 29, 2014 Hancock Jaffe received U.S. Food and Drug Administration (“FDA”) approval of the Premarket Approval Supplement associated with its new manufacturing facility, and the Company began shipping product made in this new facility in the fourth quarter of 2014.
	PhotoFix Distribution Agreement
	In 2014 CryoLife entered into an exclusive supply and distribution agreement with Genesee Biomedical, Inc. (“GBI”) to acquire the distribution rights to PhotoFix TM, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde.  PhotoFix, which was last commercially available in 2010, has received FDA 510(k) clearance and is indicated for use in intracardiac repair, including ventricular repair and atrial repair, great vessel repair and suture line buttressing, and pericardial closure.
	The agreement between CryoLife and GBI (the “GBI Agreement”) has an initial five-year term and is renewable for two one-year periods at CryoLife’s option.  Per the terms of the GBI Agreement, CryoLife is purchasing PhotoFix inventory for resale at an agreed upon transfer price and has the option to acquire the PhotoFix product line from GBI beginning in March 2015.  In January 2015 the Company received its initial shipments and launched its distribution of PhotoFix.

Hemosphere_Acquisition

Hemosphere Acquisition	3 Months Ended
	Mar. 31, 2015
Hemosphere Acquisition [Abstract]
Hemosphere Acquisition	5.  Hemosphere Acquisition
	Overview
	On May 16, 2012 CryoLife acquired Hemosphere, Inc. (“Hemosphere”) and its HeRO Graft product line, which the Company operated as a wholly owned subsidiary until December 31, 2014 when it was merged into the CryoLife, Inc. parent entity.  The HeRO Graft is a proprietary graft-based solution for ESRD hemodialysis patients with limited access options and central venous obstruction.
	Contingent Consideration
	As of the Hemosphere acquisition date, CryoLife recorded a contingent consideration liability of $1.8 million in long-term liabilities on its Summary Consolidated Balance Sheet, representing the estimated fair value of the contingent consideration expected to be paid to the former shareholders of Hemosphere upon the achievement of certain revenue-based milestones.  The acquisition agreement provides for a maximum of $4.5 million in future consideration payments through December 2015 based on specified sales targets.
	The fair value of the contingent consideration liability was estimated by discounting to present value the contingent payments expected to be made based on a probability-weighted scenario approach.  The Company applied a risk-based estimate of the probability of achieving each scenario and then applied a cost of debt based discount rate.  This fair value measurement was based on unobservable inputs, including management estimates and assumptions about future revenues, and was, therefore, classified as Level 3 within the fair value hierarchy.  The Company remeasured this liability at each reporting date and recorded changes in the fair value of the contingent consideration in other (income) expense on the Company’s Consolidated Statements of Operations and Comprehensive Income.  Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of Company revenue estimates.  As of December 31, 2014 the Company reviewed the full year revenue performance of Hemosphere for 2014 and 2013, and reviewed its 2015 annual budgets, which were updated in the fourth quarter of 2014.  As a result of this review, as of December 31, 2014 the Company believed that achievement of the minimum revenue target to trigger payment was remote, and, therefore, estimated the fair value of the contingent consideration to be zero.
	The Company recorded a gain of zero and $98,000 in the three months ended March 31, 2015 and 2014, respectively, on the remeasurement of the contingent consideration liability.  The gain in the prior year period was due to changes in the Company’s estimates, partially offset by the effect of the passage of time on the fair value measurements.  The balance of the contingent consideration liability was zero as of March 31, 2015 and December 31, 2014.

ValveXchange

ValveXchange	3 Months Ended
	Mar. 31, 2015
ValveXchange [Abstract]
ValveXchange	6.  ValveXchange
	Preferred Stock Investment
	In July 2011 the Company purchased shares of series A preferred stock of ValveXchange, Inc. (“ValveXchange”) for approximately $3.5 million.  ValveXchange is a private medical device company that was spun off from Cleveland Clinic to develop a lifetime heart valve replacement technology platform featuring exchangeable bioprosthetic leaflets.  As ValveXchange’s stock is not actively traded on any public stock exchange, and as the Company’s investment is in preferred stock, the Company initially accounted for this investment using the cost method as a long-term asset, investment in equity securities, on the Company’s Summary Consolidated Balance Sheet.
	During the fourth quarter of 2013 the Company reevaluated its investment in ValveXchange preferred stock for impairment.  Based on this analysis, the Company believed that its investment in ValveXchange was fully impaired as of December 31, 2013, and the impairment was other than temporary.  As of March 31, 2015 and December 31, 2014 the carrying value of the Company’s investment in ValveXchange preferred stock was zero.
	Loan Agreement
	In July 2011 the Company entered into an agreement with ValveXchange, as amended, to make available to ValveXchange up to $2.0 million in debt financing through a revolving credit facility (the “Loan”).  The Loan includes various affirmative and negative covenants, including financial covenant requirements, and expires on July 30, 2018, unless terminated earlier.  Amounts under the Loan earn interest at an 8% annual rate and are secured by substantially all of the tangible and intangible assets of ValveXchange.  The Company advanced $2.0 million to ValveXchange under the Loan in 2012.
	During the quarter ended December 31, 2014 CryoLife became aware of various factors, including ValveXchange’s inability to secure additional funding, its lack of capital to continue basic operations, and the likelihood of impending default on the Loan.  In December 2014 CryoLife notified ValveXchange that it was in breach of the Loan, and in January 2015, after ValveXchange failed to cure this breach, CryoLife accelerated the amounts due under the Loan.  In January 2015 ValveXchange informed CryoLife management of its intent to file for bankruptcy.  If ValveXchange does file for bankruptcy, the bankruptcy process is expected to be lengthy, and the ultimate disposition of CryoLife’s claim for amounts it is owed under the Loan is uncertain.  Given this fact pattern, CryoLife believed that its Loan became fully impaired in the fourth quarter of 2014.  As a result, during the three months ended December 31, 2014 the Company recorded other non-operating expense of $2.0 million to write-down its long-term note receivable from ValveXchange.  The net carrying value of the long-term note receivable was zero as of March 31, 2015 and December 31, 2014.
	Option Agreement
	Concurrently with the Loan described above, CryoLife entered into an option agreement with ValveXchange through which CryoLife obtained the right of first refusal to acquire ValveXchange during a period that extends through the completion of initial commercialization milestones and the right to negotiate with ValveXchange for European distribution rights.

Medafor_Matters

Medafor Matters	3 Months Ended
	Mar. 31, 2015
Medafor Matters [Abstract]
Medafor Matters	7.  Medafor Matters
	Investment in Medafor Common Stock
	In 2009 and 2010 CryoLife purchased shares of common stock in Medafor, Inc. (“Medafor”).  The Company initially recorded its investment using the cost method as a long-term asset, investment in equity securities, on the Company’s Summary Consolidated Balance Sheets.
	On October 1, 2013 C.R. Bard, Inc. (“Bard”) and its subsidiaries completed the previously announced acquisition of the outstanding shares of Medafor common stock.  The Company received an initial payment of approximately $15.4 million in the fourth quarter of 2013 for its 2.4 million shares of Medafor common stock and received an additional payment of $530,000 in the fourth quarter of 2014 related to the release of funds in escrow.    In April 2015 the Company received a payment of $891,000 related to the second scheduled release of funds in escrow, which will be recorded as a gain in the second quarter of 2015.  Based on information provided by Medafor as part of its September 24, 2013 Proxy Statement, the Company could receive additional payments totaling up to $7.0 million upon the release of funds held in escrow and the satisfaction of certain contingent milestones, measurable through June 2015.
	The Company recorded a gain on the sale of approximately $12.7 million in the fourth quarter of 2013 and $530,000 in the fourth quarter of 2014.  Subsequent payments will be recorded as an additional gain if, and when, received by the Company.
	Legal Action
	On April 28, 2014 CryoLife filed a declaratory judgment lawsuit against Bard, and its subsidiaries Davol, Inc. (“Davol”) and Medafor (collectively, “Defendants”), in the U.S. District Court for the District of Delaware (the “Court”).  CryoLife requested that the Court declare that CryoLife’s manufacture, use, offer for sale, and sale of PerClot in the U.S. does not, and would not, infringe Bard’s U.S. Patent No. 6,060,461 (the “‘461 Patent”).  In addition, CryoLife requested that the Court declare that the claims of the ‘461 Patent are invalid.  As part of the relief requested, CryoLife requested injunctive relief and an award of attorneys’ fees.
	The lawsuit against the Defendants followed the receipt by CryoLife of a letter from Medafor in September 2012 stating that PerClot, when introduced in the U.S., would infringe the ‘461 Patent when used in accordance with the method published in CryoLife’s literature and with the instructions for use.  CryoLife received FDA 510(k) clearance for the sale of PerClot Topical in April 2014, began distributing PerClot Topical in August 2014, and received IDE approval in March 2014 to begin clinical trials for PerClot in certain surgical indications.
	In June 2014 CryoLife filed an amended complaint, and Medafor filed a counterclaim for infringement in August 2014.  The Defendants also filed various motions to dismiss.  On September 19, 2014 Medafor filed a motion for a preliminary injunction, asking the Court to enjoin CryoLife’s marketing and sale of PerClot in the U.S.  In March 2015 the Court ruled that CryoLife’s declaratory judgment lawsuit against Medafor may proceed and dismissed Bard and Davol from the lawsuit.  The Court also granted Medafor’s motion for a preliminary injunction, which prohibits CryoLife from marketing, selling, and distributing PerClot in the U.S. while the litigation proceeds.  In March 2015 CryoLife ceased all marketing, sales, and distribution of PerClot, including PerClot Topical, in the U.S. in accordance with the Court’s order.  In April 2015 CryoLife filed with the Court notice of CryoLife’s appeal to the U.S. Court of Appeals for the Federal Circuit of the Court’s ruling on the preliminary injunction motion.

Inventories_And_Deferred_Prese

Inventories And Deferred Preservation Costs	3 Months Ended
	Mar. 31, 2015
Inventories And Deferred Preservation Costs [Abstract]
Inventories And Deferred Preservation Costs	8.  Inventories and Deferred Preservation Costs
	Inventories at March 31, 2015 and December 31, 2014 are comprised of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials and supplies	$	7,499	$	7,942
	Work-in-process		1,160		1,006
	Finished goods		4,854		3,791
	Total inventories	$	13,513	$	12,739
	Deferred preservation costs at March 31, 2015 and December 31, 2014 are comprised of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Cardiac tissues	$	10,973	$	10,875
	Vascular tissues		13,723		14,321
	Total deferred preservation costs	$	24,696	$	25,196

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill And Other Intangible Assets [Abstract]
Goodwill And Other Intangible Assets	9.  Goodwill and Other Intangible Assets
	Indefinite Lived Intangible Assets
	As of March 31, 2015 and December 31, 2014 the carrying values of the Company’s indefinite lived intangible assets are as follows (in thousands):
		March 31,		December 31,
		2015		2014
	Goodwill	$	11,365	$	11,365
	Procurement contracts and agreements		2,013		2,013
	Trademarks		854		853
	Based on its experience with similar agreements, the Company believes that its acquired procurement contracts and agreements have an indefinite useful life, as the Company expects to continue to renew these contracts for the foreseeable future.  The Company believes that its trademarks have an indefinite useful life as the Company currently anticipates that these trademarks will contribute to cash flows of the Company indefinitely.
	As of March 31, 2015 and December 31, 2014 the Company’s entire goodwill balance is related to its Medical Devices segment, and there has been no change from the balance recorded as of December 31, 2014.
	Definite Lived Intangible Assets
	As of March 31, 2015 and December 31, 2014 the gross carrying values, accumulated amortization, and approximate amortization periods of the Company’s definite lived intangible assets are as follows (dollars in thousands):
		Gross Carrying		Accumulated		Amortization
	31-Mar-15	Value		Amortization		Period
	Acquired technology	$	14,020	$	4,100	11	–	16	Years
	Patents		4,263		2,539			17	Years
	Distribution and manufacturing rights and know-how		4,059		1,029	11	–	12	Years
	Customer lists and relationships		3,370		873	13	–	17	Years
	Non-compete agreement		381		314			10	Years
	Other		267		59	3	–	5	Years
		Gross Carrying		Accumulated		Amortization
	31-Dec-14	Value		Amortization		Period
	Acquired technology	$	14,020	$	3,815	11	–	16	Years
	Patents		4,281		2,497			17	Years
	Distribution and manufacturing rights and know-how		4,559		989	11	–	15	Years
	Customer lists and relationships		3,370		813	13	–	17	Years
	Non-compete agreement		381		305			10	Years
	Other		461		239	1	–	5	Years
	Amortization Expense
	The following is a summary of amortization expense as recorded in general, administrative, and marketing expenses on the Company’s Summary Consolidated Statement of Operations and Comprehensive Income (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Amortization expense	$	515	$	496
	As of March 31, 2015 scheduled amortization of intangible assets for the next five years is as follows (in thousands):
		Remainder
		of 2015		2016		2017			2018		2019		2020
	Amortization expense	$	1,508	$	2,006	$	1,953		$	1,946	$	1,897	$	1,723

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Income Taxes	10.  Income Taxes
	Income Tax Expense
	The Company’s effective income tax rate was approximately 85% for the three months ended March 31, 2015, as compared to 39% for the three months ended March 31, 2014.  The Company’s income tax rate for the three months ended March 31, 2015 was unfavorably affected by the absence of the domestic production activities deduction, as the Company does not anticipate being eligible for this deduction in 2015, and by other permanent book/tax differences, which are expected to have a proportionally larger impact in 2015 than in the prior year when compared to the Company’s estimates of pretax book income.  The Company’s income tax rates for the three months ended March 31, 2015 and 2014 did not include an anticipated benefit from the research and development tax credit, which had not yet been enacted within the respective time periods.
	Deferred Income Taxes
	Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and tax return purposes.  The Company generates deferred tax assets primarily as a result of book write-downs, reserves, or impairments which are not immediately deductible for tax return purposes.  The Company acquired significant deferred tax assets, primarily net operating loss carryforwards, from its acquisitions of Hemosphere and Cardiogenesis Corporation in the second quarters of 2012 and 2011, respectively.  The Company currently estimates that a portion of its state net operating loss carryforwards will not be recoverable and has, therefore, recorded a valuation allowance against these state net operating loss carryforwards.
	As of March 31, 2015 the Company maintained a total of $2.1 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and a net deferred tax asset of $22.1 million.  As of December 31, 2014 the Company had a total of $2.1 million in valuation allowances against deferred tax assets and a net deferred tax asset of $21.9 million.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt [Abstract]
Debt	11.  Debt
	GE Credit Agreement
	On September 26, 2014 CryoLife amended and restated its credit agreement with GE Capital, extending the expiration date and amending other terms, which are discussed further below.  CryoLife’s amended and restated credit agreement with GE Capital (the “GE Credit Agreement”) provides revolving credit for working capital, permitted acquisitions, and general corporate purposes.  The GE Credit Agreement has aggregate commitments of $20.0 million for revolving loans, including swing loans, subject to a sublimit, and letters of credit, and expires on September 26, 2019.  The commitments may be reduced from time to time pursuant to the terms of the GE Credit Agreement.  The GE Credit Agreement also permits CryoLife to request a term loan in an aggregate amount of up to $25.0 million to finance the purchase price of a permitted acquisition.
	Amounts borrowed under the GE Credit Agreement are secured by substantially all of the tangible and intangible assets of CryoLife and its subsidiaries and bear interest, based on the Company’s election, at either LIBOR or GE Capital’s base rate plus the respective applicable margins.  All swing loans will, however, bear interest at the base loan rate.  Commitment fees are paid based on the unused portion of the facility.  If an event of default occurs, the applicable interest rate will increase by 2.0% per annum.  As of March 31, 2015 and December 31, 2014  the aggregate interest rate was 4.75%.  As of March 31, 2015 and December 31, 2014 the outstanding balance of the GE Credit Agreement was zero, and the remaining availability was $20.0 million.
	The GE Credit Agreement places limitations on the amount that the Company may borrow and includes various affirmative and negative covenants, including financial covenants such as a requirement that CryoLife (i) not exceed a defined leverage ratio and (ii) maintain minimum earnings subject to defined adjustments as of specified dates.  The agreement also (i) limits the payment of cash dividends, up to specified maximums and subject to satisfaction of specified conditions, (ii) requires that, after giving effect to stock repurchases, the Company maintain liquidity, as defined within the agreement, of at least $20.0 million, (iii) limits acquisitions or mergers except for certain permitted acquisitions, (iv) sets specified limits on the amount the Company can pay to purchase or redeem CryoLife common stock pursuant to a stock repurchase program and to fund estimated tax liabilities incurred by officers, directors, and employees as a result of awards of stock or stock equivalents, and (v) includes customary conditions on incurring new indebtedness.  As of March 31, 2015 the Company was in compliance with the covenants of the GE Credit Agreement.
	As required under the terms of the GE Credit Agreement, the Company is maintaining cash and cash equivalents of at least $5.0 million in accounts over which GE Capital has a first priority perfected lien.  These amounts are recorded as long-term restricted cash as of March 31, 2015 and December 31, 2014 on the Company’s Summary Consolidated Balance Sheets, as they are restricted for the term of the GE Credit Agreement.
	Interest Expense
	Interest expense was $30,000 and $61,000 for the three months ended March 31, 2015 and 2014, respectively, which included interest on debt and uncertain tax positions.

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12.  Commitments and Contingencies
	Liability Claims
	At March 31, 2015 and December 31, 2014 the Company’s estimated unreported loss liability was $1.4 million.  The related recoverable insurance amounts were $615,000 and $600,000 as of March 31, 2015 and December 31, 2014, respectively.  The Company accrues its estimate of unreported product and tissue processing liability claims as a component of other long‑term liabilities and records the related recoverable insurance amount as a component of other long‑term assets, as appropriate.  Further analysis indicated that the liability as of March 31, 2015 could have been estimated to be as high as $2.7 million, after including a reasonable margin for statistical fluctuations calculated based on actuarial simulation techniques.
	Employment Agreement
	In July 2014 the Company’s Board of Directors appointed Mr. J. Patrick Mackin as President and Chief Executive Officer (“CEO”), and the Company and Mr. Mackin entered into an employment agreement, which became effective September 2, 2014.  The employment agreement has an initial three-year term.  Beginning on the second anniversary of the effective date, and subject to earlier termination pursuant to the agreement, the employment term will, on a daily basis, automatically extend by one day.  In accordance with the agreement, on September 2, 2014, Mr. Mackin received a one-time signing bonus of $200,000, a grant of 400,000 stock options, and a performance stock award grant of 250,000 shares.  The agreement also provides for a severance payment, which would become payable upon the occurrence of certain employment termination events, including termination by the Company without cause.
	The employment agreement of the Company’s former President, CEO, and Executive Chairman, Mr. Steven G. Anderson, conferred certain benefits upon his retirement or termination of employment in conjunction with certain change in control events.  As of both March 31, 2015 and December 31, 2014 the Company had $2.2 million in accrued expenses and other current liabilities on the Summary Consolidated Balance Sheets representing benefits payable upon Mr. Anderson’s voluntary retirement.  Mr. Anderson’s employment agreement took effect on January 1, 2013 and would have terminated on December 31, 2016.
	On April 9, 2015 Mr. Anderson retired from service as an employee of the Company and a member of its Board of Directors, and entered into a Separation Agreement (the “Agreement”) with the Company.  In accordance with the Agreement, Mr. Anderson will receive an approximately $2.0 million severance payment, which had previously been accrued, an additional $400,000 in cash, 25% of the annual bonus he would have been entitled to under his employment agreement, estimated at target payout rates to be approximately $100,000, reimbursement of a Medicare supplement policy for Mr. Anderson and his spouse for the duration of their lives, accelerated vesting of all outstanding and unvested stock options and awards, and reimbursement of attorneys’ fees not to exceed $20,000.  The Company will record the incremental expense of approximately $1.2 million related to this agreement in the second quarter of 2015.  The severance and cash payments are expected to be made in October 2015, six months after Mr. Anderson’s retirement.  The annual bonus payment is expected to be made in February 2016 at the same time as annual bonus payments, if any, are made to the Company’s officers.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2015
Shareholders' Equity [Abstract]
Shareholders' Equity	13.  Shareholders’ Equity
	Common Stock Repurchase
	In February 2013 the Company’s Board of Directors authorized the purchase of up to $15.0 million of its common stock through October 31, 2014.  For the year ended December 31, 2014 the Company purchased approximately 585,000 shares for an aggregate purchase price of $5.6 million.  These shares were recorded, at cost, as part of treasury stock on the Company’s Summary Consolidated Balance Sheet.  In the three months ended March 31, 2015 the Company did not repurchase any common stock under a repurchase program, as no formal repurchase program was in effect during 2015.
	Cash Dividends
	The Company initiated a quarterly cash dividend of $0.025 per share of common stock outstanding in the third quarter of 2012 and increased this dividend to $0.0275 per share in the second quarter of 2013 and $0.03 per share in the second quarter of 2014.  The Company made dividend payments of $850,000 and $772,000 from cash on hand for the three months ended March 31, 2015 and 2014, respectively.  The dividend payments were recorded as a reduction to retained earnings on the Company’s Summary Consolidated Balance Sheets.

Stock_Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2015
Stock Compensation [Abstract]
Stock Compensation	14.  Stock Compensation
	Overview
	The Company has stock option and stock incentive plans for employees and non-employee Directors that provide for grants of restricted stock awards (“RSAs”), performance stock awards (“PSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of Company common stock at exercise prices generally equal to the fair values of such stock at the dates of grant.  The Company also maintains a shareholder approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of its employees.  The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85% of the market price at the beginning or end of each offering period.
	Equity Grants
	During the three months ended March 31, 2015 the Compensation Committee of the Company’s Board of Directors authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 276,000 shares and had an aggregate market value of $3.0 million.  The PSUs granted in 2015 represent the right to receive from 60% to 150% of the target number of shares of common stock.  The performance component of PSU awards granted in 2015 is based on attaining specified levels of adjusted EBITDA, inventory, and accounts receivable, as defined in the PSU grant documents, for the 2015 calendar year.  The Company currently believes that achievement of the performance component is probable, and will reevaluate this likelihood on a quarterly basis.
	During the three months ended March 31, 2014 the Compensation Committee of the Company’s Board of Directors authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, counting PSUs at target levels, together totaled 326,000 shares and had an aggregate grant date market value of $3.3 million.  The PSUs granted in 2014 represented the right to receive from 50% to 150% of the target number of shares of common stock.  The performance component of PSU awards granted in 2014 was based on attaining specified levels of adjusted EBITDA, as defined in the PSU grant documents, for the 2014 calendar year.  The PSUs granted in 2014 earned 50% of the target number of shares.
	The Compensation Committee of the Company’s Board of Directors authorized from approved stock incentive plans, grants of stock options to purchase a total of 283,000 and 162,000 shares to certain Company officers during the three months ended March 31, 2015 and 2014.  The exercise prices of the options were equal to the closing stock prices on their respective grant dates.
	Employees purchased common stock totaling 36,000 and 59,000 shares in the three months ended March 31, 2015 and 2014, respectively, through the Company’s ESPP.
	Stock Compensation Expense
	The following weighted‑average assumptions were used to determine the fair value of options:
		Three Months Ended				Three Months Ended
		31-Mar-15				31-Mar-14
		Stock Options		ESPP Options		Stock Options		ESPP Options
	Expected life of options		4.75 Years		.50 Years		4.25 Years		.50 Years
	Expected stock price volatility		0.45		0.34		0.55		0.34
	Dividends		1.09%		1.06%		1.10%		0.99%
	Risk-free interest rate		1.51%		0.12%		1.19%		0.10%
	The following table summarizes total stock compensation expenses prior to the capitalization of amounts into deferred preservation and inventory costs (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	RSA, PSA, RSU, and PSU expense	$	865	$	712
	Stock option and ESPP option expense		308		207
	Total stock compensation expense	$	1,173	$	919
	Included in the total stock compensation expense, as applicable in each period, were expenses related to RSAs, PSAs, RSUs, PSUs, and stock options issued in each respective year, as well as those issued in prior periods that continued to vest during the period, and compensation related to the Company’s ESPP.  These amounts were recorded as stock compensation expense and were subject to the Company’s normal allocation of expenses to deferred preservation costs and inventory costs.  The Company capitalized $36,000 and $74,000 in the three months ended March 31, 2015 and 2014, respectively, of the stock compensation expense into its deferred preservation costs and inventory costs.
	As of March 31, 2015 the Company had total unrecognized compensation costs of $6.9 million related to RSAs, PSAs, RSUs, and PSUs, and $2.9 million related to unvested stock options before considering the effect of expected forfeitures.  As of March 31, 2015 this expense is expected to be recognized over a weighted-average period of 1.6 years for RSAs, 2.4 years for PSAs, 2.2 years for RSUs, 1.3 years for PSUs, and 2.4 years for stock options.

Loss_Income_Per_Common_Share

(Loss) Income Per Common Share	3 Months Ended
	Mar. 31, 2015
(Loss) Income Per Common Share [Abstract]
(Loss) Income Per Common Share	15.  (Loss) Income Per Common Share
	The following table sets forth the computation of basic and diluted (loss) income per common share (in thousands, except per share data):
		Three Months Ended
		March 31,
	Basic (loss) income per common share	2015		2014
	Net (loss) income	$	-274	$	1,059
	Net loss (income) allocated to participating securities		7		-21
	Net (loss) income allocated to common shareholders	$	-267	$	1,038
	Basic weighted-average common shares outstanding		27,523		27,376
	Basic (loss) income per common share	$	-0.01	$	0.04
		Three Months Ended
		March 31,
	Diluted (loss) income per common share	2015		2014
	Net (loss) income	$	-274	$	1,059
	Net loss (income) allocated to participating securities		7		-21
	Net (loss) income allocated to common shareholders	$	-267	$	1,038
	Basic weighted-average common shares outstanding		27,523		27,376
	Effect of dilutive stock options and awardsa		--		1,087
	Diluted weighted-average common shares outstanding		27,523		28,463
	Diluted (loss) income per common share	$	-0.01	$	0.04
	___________________
	aThe Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to (loss) income per common share.  Accordingly, stock options to purchase a weighted-average 738,000 shares and 131,000 shares for the three months ended March 31, 2015 and 2014, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Information [Abstract]
Segment Information	16.  Segment Information
	The Company has two reportable segments organized according to its products and services: Medical Devices and Preservation Services.  The Medical Devices segment includes external revenues from product sales of BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, ProCol, and PhotoFix.  The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues.  There are no intersegment revenues.
	The primary measure of segment performance, as viewed by the Company’s management, is segment gross margin, or net external revenues less cost of products and preservation services.  The Company does not segregate assets by segment; therefore, asset information is excluded from the segment disclosures below.
	The following table summarizes revenues, cost of products and preservation services, and gross margins for the Company’s operating segments (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Revenues:
	Medical devices	$	19,391	$	19,455
	Preservation services		14,440		16,276
	Total revenues		33,831		35,731
	Cost of products and preservation services:
	Medical devices		5,033		3,801
	Preservation services		9,131		9,457
	Total cost of products and preservation services		14,164		13,258
	Gross margin:
	Medical devices		14,358		15,654
	Preservation services		5,309		6,819
	Total gross margin	$	19,667	$	22,473
	The following table summarizes net revenues by product and preservation services (in thousands):
		Three Months Ended
		March 31,
		2015		2014
	Products:
	BioGlue and BioFoam	$	14,042	$	15,240
	PerClot		976		916
	CardioGenesis cardiac laser therapy		2,137		1,684
	HeRO Graft		1,860		1,615
	ProCol		204		--
	PhotoFix		172		--
	Total products		19,391		19,455
	Preservation services:
	Cardiac tissue		6,663		7,190
	Vascular tissue		7,777		9,086
	Total preservation services		14,440		16,276
	Total revenues	$	33,831	$	35,731

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Financial Instruments [Abstract]
Summary Of Financial Instruments Measured At Fair Value
	31-Mar-15	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	20,023	$	--	$	--	$	20,023
	Restricted securities:
	Money market funds		828		--		--		828
	Total assets	$	20,851	$	--	$	--	$	20,851
	31-Dec-14	Level 1		Level 2		Level 3		Total
	Cash equivalents:
	Money market funds	$	18,213	$	--	$	--	$	18,213
	Restricted securities:
	Money market funds		884		--		--		884
	Total assets	$	19,097	$	--	$	--	$	19,097

Cash_Equivalents_And_Restricte1

Cash Equivalents And Restricted Cash And Securities (Tables)	3 Months Ended
	Mar. 31, 2015
Cash Equivalents And Restricted Cash And Securities [Abstract]
Summary Of Cash Equivalents And Marketable Securities
				Unrealized		Estimated
				Holding		Market
	31-Mar-15	Cost Basis		Gains		Value
	Cash equivalents:
	Money market funds	$	20,023	$	--	$	20,023
	Restricted cash and securities:
	Cash		5,000		--		5,000
	Money market funds		828		--		828
				Unrealized		Estimated
				Holding		Market
	31-Dec-14	Cost Basis		Gains		Value
	Cash equivalents:
	Money market funds	$	18,213	$	--	$	18,213
	Restricted cash and securities:
	Cash		5,000		--		5,000
	Money market funds		884		--		884

Inventories_And_Deferred_Prese1

Inventories And Deferred Preservation Costs (Tables)	3 Months Ended
	Mar. 31, 2015
Inventories And Deferred Preservation Costs [Abstract]
Schedule Of Inventories
		March 31,		December 31,
		2015		2014
	Raw materials and supplies	$	7,499	$	7,942
	Work-in-process		1,160		1,006
	Finished goods		4,854		3,791
	Total inventories	$	13,513	$	12,739
Schedule Of Deferred Preservation Costs
		March 31,		December 31,
		2015		2014
	Cardiac tissues	$	10,973	$	10,875
	Vascular tissues		13,723		14,321
	Total deferred preservation costs	$	24,696	$	25,196

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Carrying Values Of Indefinite Lived Intangible Assets		March 31,		December 31,
		2015		2014
	Goodwill	$	11,365	$	11,365
	Procurement contracts and agreements		2,013		2,013
	Trademarks		854		853
Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Periods Of Definite Lived Intangible Assets
		Gross Carrying		Accumulated		Amortization
	31-Mar-15	Value		Amortization		Period
	Acquired technology	$	14,020	$	4,100	11	–	16	Years
	Patents		4,263		2,539			17	Years
	Distribution and manufacturing rights and know-how		4,059		1,029	11	–	12	Years
	Customer lists and relationships		3,370		873	13	–	17	Years
	Non-compete agreement		381		314			10	Years
	Other		267		59	3	–	5	Years
		Gross Carrying		Accumulated		Amortization
	31-Dec-14	Value		Amortization		Period
	Acquired technology	$	14,020	$	3,815	11	–	16	Years
	Patents		4,281		2,497			17	Years
	Distribution and manufacturing rights and know-how		4,559		989	11	–	15	Years
	Customer lists and relationships		3,370		813	13	–	17	Years
	Non-compete agreement		381		305			10	Years
	Other		461		239	1	–	5	Years
Summary Of Amortization Expense
		Three Months Ended
		March 31,
		2015		2014
	Amortization expense	$	515	$	496
Scheduled Amortization Of Intangible Assets For Next Five Years		Remainder
		of 2015		2016		2017			2018		2019		2020
	Amortization expense	$	1,508	$	2,006	$	1,953		$	1,946	$	1,897	$	1,723

Stock_Compensation_Tables

Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Compensation [Abstract]
Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options
		Three Months Ended				Three Months Ended
		31-Mar-15				31-Mar-14
		Stock Options		ESPP Options		Stock Options		ESPP Options
	Expected life of options		4.75 Years		.50 Years		4.25 Years		.50 Years
	Expected stock price volatility		0.45		0.34		0.55		0.34
	Dividends		1.09%		1.06%		1.10%		0.99%
	Risk-free interest rate		1.51%		0.12%		1.19%		0.10%
Summary Of Stock Compensation Expenses
		Three Months Ended
		March 31,
		2015		2014
	RSA, PSA, RSU, and PSU expense	$	865	$	712
	Stock option and ESPP option expense		308		207
	Total stock compensation expense	$	1,173	$	919

Loss_Income_Per_Common_Share_T

(Loss) Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2015
(Loss) Income Per Common Share [Abstract]
Computation Of Basic And Diluted (Loss) Income Per Common Share
		Three Months Ended
		March 31,
	Basic (loss) income per common share	2015		2014
	Net (loss) income	$	-274	$	1,059
	Net loss (income) allocated to participating securities		7		-21
	Net (loss) income allocated to common shareholders	$	-267	$	1,038
	Basic weighted-average common shares outstanding		27,523		27,376
	Basic (loss) income per common share	$	-0.01	$	0.04
		Three Months Ended
		March 31,
	Diluted (loss) income per common share	2015		2014
	Net (loss) income	$	-274	$	1,059
	Net loss (income) allocated to participating securities		7		-21
	Net (loss) income allocated to common shareholders	$	-267	$	1,038
	Basic weighted-average common shares outstanding		27,523		27,376
	Effect of dilutive stock options and awardsa		--		1,087
	Diluted weighted-average common shares outstanding		27,523		28,463
	Diluted (loss) income per common share	$	-0.01	$	0.04
	___________________
	aThe Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to (loss) income per common share.  Accordingly, stock options to purchase a weighted-average 738,000 shares and 131,000 shares for the three months ended March 31, 2015 and 2014, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Information [Abstract]
Revenues, Cost Of Services And Products, And Gross Margins For Operating Segments
		Three Months Ended
		March 31,
		2015		2014
	Revenues:
	Medical devices	$	19,391	$	19,455
	Preservation services		14,440		16,276
	Total revenues		33,831		35,731
	Cost of products and preservation services:
	Medical devices		5,033		3,801
	Preservation services		9,131		9,457
	Total cost of products and preservation services		14,164		13,258
	Gross margin:
	Medical devices		14,358		15,654
	Preservation services		5,309		6,819
	Total gross margin	$	19,667	$	22,473
Summary Of Net Revenues By Product
		Three Months Ended
		March 31,
		2015		2014
	Products:
	BioGlue and BioFoam	$	14,042	$	15,240
	PerClot		976		916
	CardioGenesis cardiac laser therapy		2,137		1,684
	HeRO Graft		1,860		1,615
	ProCol		204		--
	PhotoFix		172		--
	Total products		19,391		19,455
	Preservation services:
	Cardiac tissue		6,663		7,190
	Vascular tissue		7,777		9,086
	Total preservation services		14,440		16,276
	Total revenues	$	33,831	$	35,731

Financial_Instruments_Summary_

Financial Instruments (Summary Of Financial Instruments Measured At Fair Value) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$20,851	$19,097
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	20,023	18,213
Restricted securities	828	884
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	20,851	19,097
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	20,023	18,213
Restricted securities	828	884
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Restricted securities

Cash_Equivalents_And_Restricte2

Cash Equivalents And Restricted Cash And Securities (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Long-term restricted cash and securities	$5,000,000		5,000,000
Gains or losses realized on cash equivalents	0	0
Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Short-term restricted securities	828,000		884,000
No Maturity Date [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Long-term restricted cash and securities	5,000,000		5,000,000
Maturity Date Within Three Months [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	234,000		622,000
Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	594,000		262,000
GE Credit Agreement [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Long-term restricted cash and securities	$5,000,000		5,000,000
Minimum [Member] | Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities, period for maturity date	3 months		3 months
Maximum [Member] | Maturity Date Within Three Months [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities, period for maturity date	3 months		3 months
Maximum [Member] | Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities, period for maturity date	1 year		1 year

Cash_Equivalents_And_Restricte3

Cash Equivalents And Restricted Cash And Securities (Summary Of Cash Equivalents And Marketable Securities) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Cash [Member] | Restricted Cash And Securities [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	$5,000	$5,000
Unrealized Holding Gains (Losses)
Estimated Market Value	5,000	5,000
Money Market Funds [Member] | Cash Equivalents [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	20,023	18,213
Unrealized Holding Gains (Losses)
Estimated Market Value	20,023	18,213
Money Market Funds [Member] | Restricted Cash And Securities [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	828	884
Unrealized Holding Gains (Losses)
Estimated Market Value	$828	$884

Distribution_Agreements_Detail

Distribution Agreements (Details) (USD $)	1 Months Ended		12 Months Ended	3 Months Ended
	Jan. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Mar. 31, 2014
		item		item
Hancock Jaffe Laboratories, Inc. [Member]
Distribution Agreement [Line Items]
Initial term of contract for distribution rights for ProCol		3 years
Number of contract renewals		2
Term of contract renewals		1 year
Amount of payment	$576,000		$1,700,000
Genesee Biomedical, Inc. [Member]
Distribution Agreement [Line Items]
Initial term of contract for distribution rights for ProCol				5 years
Number of contract renewals				2
Term of contract renewals				1 year

Hemosphere_Acquisition_Details

Hemosphere Acquisition (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	16-May-12
Class of Stock [Line Items]
Fair value of contingent consideration				$1,800,000
Gain (loss) on revaluation of contingent consideration	0	98,000
Contingent consideration liability	0		0
Hemosphere [Member]
Class of Stock [Line Items]
Maximum amount of future consideration payment				$4,500,000

ValveXchange_Details

ValveXchange (Details) (USD $)	3 Months Ended	1 Months Ended
	Dec. 31, 2014	Jul. 31, 2011	Mar. 31, 2015	Dec. 31, 2012
Schedule of Cost-method Investments [Line Items]
Other non-operating expense recorded to write-down long-term note receivable from ValveXchange	$2,000,000
Long-Term Notes Receivable [Member]
Schedule of Cost-method Investments [Line Items]
Preferred stock carrying value	0		0
ValveXchange, Inc. [Member]
Schedule of Cost-method Investments [Line Items]
Loans receivable, revolving credit line, expiration date		30-Jul-18
Loans receivable, revolving credit line, interest rate		8.00%
Amount of loan advanced				2,000,000
ValveXchange, Inc. [Member] | Revolving Credit Facility [Member]
Schedule of Cost-method Investments [Line Items]
Loans receivable, revolving credit line, maximum capacity		2,000,000
Series A Preferred Stock [Member] | ValveXchange, Inc. [Member]
Schedule of Cost-method Investments [Line Items]
Preferred stock purchased, value		3,500,000
Preferred stock carrying value	$0		$0

Medafor_Matters_Details

Medafor Matters (Details) (USD $)	0 Months Ended		3 Months Ended		0 Months Ended
Share data in Millions, unless otherwise specified	Oct. 21, 2013	Oct. 24, 2014	Dec. 31, 2014	Dec. 31, 2013	Apr. 24, 2015	Jun. 30, 2015
Medafor Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Additional payment received from C.R. Bard for acquisition of outstanding shares	$15,400,000
Shares of Medafor common stock acquired by C.R. Bard	2.4
C.R. Bard, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Additional payment received from C.R. Bard for acquisition of outstanding shares		530,000
Gain on sale of outstanding shares of common stock			530,000	12,700,000
C.R. Bard, Inc. [Member] | Scenario, Forecast [Member]
Subsidiary or Equity Method Investee [Line Items]
Additional payments that could be received						7,000,000
C.R. Bard, Inc. [Member] | Subsequent Event [Member]
Subsidiary or Equity Method Investee [Line Items]
Additional payment received from C.R. Bard for acquisition of outstanding shares					$891,000

Deferred_Preservation_Costs_An

Deferred Preservation Costs And Inventories (Schedule Of Inventories) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventories And Deferred Preservation Costs [Abstract]
Raw materials and supplies	$7,499	$7,942
Work-in-process	1,160	1,006
Finished goods	4,854	3,791
Total inventories	$13,513	$12,739

Deferred_Preservation_Costs_An1

Deferred Preservation Costs And Inventories (Schedule Of Deferred Preservation Costs) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Deferred Preservation Costs [Line Items]
Total deferred preservation costs	$24,696	$25,196
Cardiac Tissues [Member]
Deferred Preservation Costs [Line Items]
Total deferred preservation costs	10,973	10,875
Vascular Tissues [Member]
Deferred Preservation Costs [Line Items]
Total deferred preservation costs	$13,723	$14,321

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets (Schedule Of Carrying Values Of Indefinite Lived Intangible Assets)(Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$11,365,000	$11,365,000
Change in goodwill	0
Procurement Contracts And Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets	2,013,000	2,013,000
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets	$853,000	$854,000

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Periods Of Definite Lived Intangible Assets) (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$14,020	$14,020
Accumulated amortization	4,100	3,815
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,263	4,281
Accumulated amortization	2,539	2,497
Amortization Period	17 years	17 years
Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,059	4,559
Accumulated amortization	1,029	989
Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,370	3,370
Accumulated amortization	873	813
Non-Compete Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	381	381
Accumulated amortization	314	305
Amortization Period	10 years	10 years
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	267	461
Accumulated amortization	$59	$239
Minimum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	13 years	13 years
Minimum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	3 years	1 year
Maximum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	16 years	16 years
Maximum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	12 years	15 years
Maximum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	17 years	17 years
Maximum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	5 years	5 years

Goodwill_And_Other_Intangible_4

Goodwill And Other Intangible Assets (Summary Of Amortization Expense) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Goodwill And Other Intangible Assets [Abstract]
Amortization expense	$515	$496

Goodwill_And_Other_Intangible_5

Goodwill And Other Intangible Assets (Scheduled Amortization Of Intangible Assets For Next Five Years) (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Goodwill And Other Intangible Assets [Abstract]
Amortization expense, Remainder of 2015	$1,508
Amortization expense, 2016	2,006
Amortization expense, 2017	1,953
Amortization expense, 2018	1,946
Amortization expense, 2019	1,897
Amortization expense, 2020	$1,723

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Taxes [Abstract]
Effective income tax rate	85.00%	39.00%
Valuation allowances against deferred tax assets	$2.10		$2.10
Net deferred tax asset	$22.10		$21.90

Debt_Details

Debt (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Interest expense	$30,000	$61,000
GE Credit Agreement [Member]
Line of Credit Facility [Line Items]
Revolving credit facility, aggregate amount	20,000,000
Term loan available upon request, aggregate amount	25,000,000
Revolving credit facility, expiration date	26-Sep-19
Increase in applicable interest rate, per annum, if default occurs	2.00%
Revolving credit facility, aggregate interest rate	4.75%		4.75%
Revolving credit facility, outstanding balance	0		0
Revolving credit facility, remaining availability	20,000,000		20,000,000
Minimum [Member] | GE Credit Agreement [Member]
Line of Credit Facility [Line Items]
Revolving credit facility, restriction on cash and cash equivalents	5,000,000
Revolving credit facility, liquidity requirement after effect to stock repurchase	$20,000,000

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	3 Months Ended			0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2015	Sep. 02, 2014	Dec. 31, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unreported loss liability	$1,400,000				$1,400,000
Recoverable insurance amounts	615,000				600,000
Liability estimated after a reasonable margin for statistical fluctuations	2,700,000
Issuance of grants of stock options to CEO	283,000	162,000
Scenario, Forecast [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Incremental expense related to agreement			1,200,000
Chief Executive Officer [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Term of employment, effective September 2, 2014	3 years
CEO signing bonus				200,000
Issuance of grants of stock options to CEO				400,000
Issuance of grants of performance stock awards to CEO				250,000
Severance payment	2,000,000
Additional cash payment for Separation Agreement	400,000
Percentage of CEO annual bonus for Separation Agreement	25.00%
Amount of CEO annual bonus for Separation Agreement	100,000
Maximum [Member] | Chief Executive Officer [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Reimbursement of attorneys' fees	20,000
CEO Post Employment Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accrued expenses and other current liabilities payable upon the CEO's voluntary retirement	$2,200,000				$2,200,000

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	0 Months Ended			3 Months Ended		12 Months Ended
	22-May-14	28-May-13	Aug. 21, 2012	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Feb. 01, 2013
Shareholders' Equity [Abstract]
Common stock repurchase, authorized amount							$15,000,000
Stock repurchased during period, shares						585,000
Stock repurchased during period, aggregate purchase price						5,600,000
Quarterly cash dividend per share of common stock outstanding approved	$0.03	$0.03	$0.03	$0.03	$0.03
Dividend payment from cash on hand				$850,000	$772,000

Stock_Compensation_Narrative_D

Stock Compensation (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees	85.00%
Actual percentage of target number of shares of common stock granted as Performance Stock Units			50.00%
Granted, Shares	283,000	162,000
Employees purchased common stock, shares	36,000	59,000
Capitalized stock compensation expense	$36,000	$74,000
RSAs, RSUs, PSUs, And PSAs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	6,900,000
RSAs, RSUs, And PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized from approved stock incentive plans to certain Company officers, non-employee Directors, and certain eligible employees, shares	276,000	326,000
Aggregate market value of shares granted under approved stock incentive plans	3,000,000	3,300,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$2,900,000
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	2 years 4 months 24 days
Performance Stock Awards (PSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	2 years 4 months 24 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	2 years 2 months 12 days
Restricted Stock Awards (RSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 7 months 6 days
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 3 months 18 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units	60.00%	50.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units	150.00%	150.00%

Stock_Compensation_Schedule_Of

Stock Compensation (Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options) (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	4 years 9 months	4 years 3 months
Expected stock price volatility	45.00%	55.00%
Dividend yield	1.09%	1.10%
Risk-free interest rate	1.51%	1.19%
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	6 months	6 months
Expected stock price volatility	34.00%	34.00%
Dividend yield	1.06%	0.99%
Risk-free interest rate	0.12%	0.10%

Stock_Compensation_Summary_Of_

Stock Compensation (Summary Of Stock Compensation Expenses) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$1,173	$919
RSA, PSA, RSU, And PSU Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	865	712
Stock Option And ESPP Option Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$308	$207

Loss_Income_Per_Common_Share_D

(Loss) Income Per Common Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
(Loss) Income Per Common Share [Abstract]
Net (loss) income	($274)	$1,059
Net loss (income) allocated to participating securities, basic	7	-21
Net (loss) income allocated to common shareholders, basic	-267	1,038
Basic weighted-average common shares outstanding	27,523,000	27,376,000
Basic income per common share	($0.01)	$0.04
Net loss (income) allocated to participating securities, diluted	7	-21
Net (loss) income allocated to common shareholders, diluted	($267)	$1,038
Effect of dilutive stock options and awards		1,087,000	[1]
Diluted weighted-average common shares outstanding	27,523,000	28,463,000
Diluted income per common share	($0.01)	$0.04
Antidilutive securities excluded from computation of earnings per share	738,000	131,000
[1]	The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to (loss) income per common share. Accordingly, stock options to purchase a weighted-average 738,000 shares and 131,000 shares for the three months ended March 31, 2015 and 2014, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.

Segment_Information_Revenues_C

Segment Information (Revenues, Cost Of Services And Products, And Gross Margins For Operating Segments) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	segment
Segment Reporting Information [Line Items]
Number of reportable segments	2
Total revenues	$33,831	$35,731
Total cost of products and preservation services	14,164	13,258
Total gross margin	19,667	22,473
Medical Devices [Member]
Segment Reporting Information [Line Items]
Total revenues	19,391	19,455
Total cost of products and preservation services	5,033	3,801
Total gross margin	14,358	15,654
Preservation Services [Member]
Segment Reporting Information [Line Items]
Total revenues	14,440	16,276
Total cost of products and preservation services	9,131	9,457
Total gross margin	$5,309	$6,819

Segment_Information_Summary_Of

Segment Information (Summary Of Net Revenues By Product) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Product Information [Line Items]
Total revenues	$33,831	$35,731
BioGlue And BioFoam [Member]
Product Information [Line Items]
Total revenues	14,042	15,240
PerClot [Member]
Product Information [Line Items]
Total revenues	976	916
CardioGenesis Cardiac Laser Therapy [Member]
Product Information [Line Items]
Total revenues	2,137	1,684
HeRO Graft [Member]
Product Information [Line Items]
Total revenues	1,860	1,615
ProCol [Member]
Product Information [Line Items]
Total revenues	204
PhotoFix [Member]
Product Information [Line Items]
Total revenues	172
Total Products [Member]
Product Information [Line Items]
Total revenues	19,391	19,455
Cardiac Tissue [Member]
Product Information [Line Items]
Total revenues	6,663	7,190
Vascular Tissue [Member]
Product Information [Line Items]
Total revenues	7,777	9,086
Total Preservation Services [Member]
Product Information [Line Items]
Total revenues	$14,440	$16,276